Sionna Therapeutics, Inc. (SION) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - Sionna Therapeutics aims to revolutionize the treatment paradigm in cystic fibrosis (CF) by utilizing first-in-class NBD1 stabilizers, which have the potential to provide clinically meaningful benefits beyond the current standard of care [2] - The company was established in late 2019 as a spinout from Sanofi, with its scientific foundation originating from Genzyme over 15 years ago, highlighting the extensive research and investment that has contributed to its current position [2] Market Position - Sionna Therapeutics is well positioned to disrupt the CF market positively, indicating a strategic focus on innovative treatment solutions [3]